Table 2.

Distribution of treatment regimen among the HCV-infected patients with CKD and HCV-only cohorts

Treatment regimen	HCV with CKD [n = 236]	HCV-only [n = 3202]
Sofosbuvir/simeprevir	75 (31.78)	835 (26.08)
Sofosbuvir/simeprevir + ribavirin	10 (4.24)	127 (3.97)
Sofosbuvir + ribavirin	54 (22.88)	804 (25.11)
Ledipasvir/sofosbuvir	89 (37.71)	1394 (43.54)
Ledipasvir/sofosbuvir + ribavirin	5 (2.12)	30 (0.94)
Ombitasvir/paritaprevir/ritonavir + dasabuvir	3 (1.27)	12 (0.37)

Data are expressed as n (%)

CKD chronic kidney disease, HCV hepatitis C virus